Benjamin Solomon

Impact of COVID-19 on Cancer Service Delivery; a follow up international survey of oncology clinicians

Grace Chazan, Fanny Franchini, Marliese Alexander, Susana Banerjee, Linda Mileshkin, Prunella Blinman, Rob Zielinski, Deme Karikios, Nick Pavlakis, Solange Peters, Florian Lordick, David Ball, Gavin Wright, Maarten IJzerman, Benjamin J Solomon

Journal article  |  2021  |  ESMO Open

Immunotherapy in oncogene addicted non-small cell lung cancer

L McLean, JL Leal, BJ Solomon, T John

Journal article  |  2021  |  Translational Lung Cancer Research

The use of immune checkpoint inhibitors (ICIs) targeting the programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD..

CRISPR/Cas9 mediated deletion of the adenosine A2A receptor enhances CAR T cell efficacy

Lauren Giuffrida, Kevin Sek, Melissa A Henderson, Junyun Lai, Amanda XY Chen, Deborah Meyran, Kirsten L Todd, Emma Petley, Sherly Mardiana, Christina Molck, Gregory D Stewart, Benjamin J Solomon, Ian A Parish, Paul J Neeson, Simon J Harrison, Lev M Kats, Imran G House, Phillip K Darcy, Paul A Beavis

Journal article  |  2021  |  NATURE COMMUNICATIONS

Adenosine is an immunosuppressive factor that limits anti-tumor immunity through the suppression of multiple immune subsets includ..

Response to selpercatinib versus prior systemic therapy in patients (pts) with RET fusion non-small-cell lung cancer (NSCLC).

Alexander E Drilon, Oliver Gautschi, Benjamin Besse, Vivek Subbiah, Daniel Shao-Weng Tan, Keunchil Park, Filippo G De Braud, Guzman Alonso, Juergen Wolf, Victoria Soldatenkova, Pearl Plernjit French, Aimee K Lin, Koichi Goto, Benjamin J Solomon

Conference Proceedings  |  2021  |  Journal of Clinical Oncology

9032 Background: Selpercatinib, a first-in-class highly selective, potent, CNS-active RET kinase inhibitor, is approved in multip..

Identification of good and poor prognosis HPV associated oropharyngeal cancer based on CD103 immune cell expression in patients treated with cetuximab and radiotherapy on TROG 12.01 and De-ESCALaTE randomized trials.

Danny Rischin, Hisham Mohamed Mehanna, Richard J Young, Mathias Bressel, Janet Dunn, June Corry, Tessa Fulton-Lieuw, Gulnaz Iqbal, Lizbeth M Kenny, Sandro Porceddu, Christopher Wratten, Max Robinson, Benjamin J Solomon

Conference Proceedings  |  2021  |  Journal of Clinical Oncology

109 Background: Trials in human papilloma virus associated oropharyngeal squamous cell carcinoma (HPVOPSCC), substituting cetuxim..

Updated overall efficacy and safety of selpercatinib in patients (pts) with RET fusion non-small cell lung cancer (NSCLC).

Benjamin Besse, Alexander E Drilon, Benjamin J Solomon, Vivek Subbiah, Daniel Shao-Weng Tan, Keunchil Park, Filippo G De Braud, Guzman Alonso, Juergen Wolf, Victoria Soldatenkova, Aimee K Lin, Pearl Plernjit French, Koichi Goto, Oliver Gautschi

Conference Proceedings  |  2021  |  Journal of Clinical Oncology

9065 Background: Selpercatinib, a first-in-class highly selective and potent, CNS-active RET kinase inhibitor, is approved in mul..

Early circulating tumor (ct) DNA dynamics and efficacy of lorlatinib: Analysis from the CROWN study.

Ross A Soo, Jean-Francois Martini, Anthonie J van der Wekken, Shunsuke Teraoka, Alice T Shaw, Deborah Shepard, Anna Maria Calella, Anna Polli, Francesca Toffalorio, Pascale Tomasini, Chao-Hua Chiu, Dariusz Kowalski, Hye Ryun Kim, Benjamin J Solomon

Conference Proceedings  |  2021  |  Journal of Clinical Oncology

9011 Background: Lorlatinib, a third-generation ALK tyrosine kinase inhibitor, significantly improved progression-free survival (..

EGFR Exon 20 Insertion Mutations: Clinicopathological Characteristics and Treatment Outcomes in Advanced Non-Small Cell Lung Cancer.

Jose Luis Leal, Marliese Alexander, Malinda Itchins, Gavin M Wright, Steven Kao, Brett GM Hughes, Nick Pavlakis, Stephen Clarke, Anthony J Gill, Hannah Ainsworth, Benjamin Solomon, Thomas John

Journal article  |  2021  |  Clin Lung Cancer

BACKGROUND: Epidermal growth factor receptor gene (EGFR) exon 20 insertion (ex20-ins) mutations are an uncommon and heterogeneous ..

Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs

E Felip, AT Shaw, A Bearz, DR Camidge, BJ Solomon, JR Bauman, TM Bauer, S Peters, F Toffalorio, A Abbattista, H Thurm, G Peltz, R Wiltshire, B Besse

Journal article  |  2021  |  ANNALS OF ONCOLOGY

BACKGROUND: Lorlatinib, a potent, brain-penetrant, third-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TK..

PACIFIC-R: Real-world characteristics of unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy

F McDonald, F Mornex, MC Garassino, AR Filippi, D Christoph, VD Haakensen, A Agbarya, M Van den Heuvel, P Vercauter, C Chouaid, E Pichon, S Siva, L Steinbusch, I Peretz, B Solomon, L Decoster, W Sawyer, A Allen, M Licour, N Girard

Conference Proceedings  |  2021  |  JOURNAL OF THORACIC ONCOLOGY